United StatesPsychedelic drops depression scores 19.5 points, placebo 11.9.
Helus Pharma reported the Phase 3 results Monday, and a number of serious adverse events raise safety questions.
At 12 weeks the gap held: 16.9 points against 9.9 on placebo, with patients also on standard antidepressants.
The company announced the results itself, and no peer-reviewed paper has yet confirmed them.
How each outlet framed it
- STAT
- leads with the Phase 3 efficacy numbers (MADRS -19.5 vs -11.9 at six weeks) before the serious adverse events, reversing the safety-first framing
Sources: STAT